Harrow, Inc. · NASDAQ:HROW

Harrow — Imprimis Pharmaceuticals — Investor Presentation (October 2014)

7 slides from Harrow's investor presentation, Oct 17, 2014

Slide 1: Slide 1
Slide 2: October 2014
OCTOBER 2014 Imprimis ier www.GoDropless.com SE Lapvcill MEIC BTV Jiical rat . ' 5 J 7 Imprimis Pharmaceuticals (NASDAQ: IMMY) is currently selling a proprietary single-dose formulation containing triamcinolone acetonide and moxifloxacin hydrochloride (Tri-Moxi) and a second formulation with vancomy
Slide 3: Slide 3
Slide 4: Slide 4
Slide 5: 2014 and 2015 Goals
www.imprimisPharma.com www.GoDropless.com 2014 AND 2015 GOALS Ophthalmology * Continue Go Dropless™ adoption momentum * Introduce new ophthalmology formulations + Normalize Tri-Moxi pricing Non-Ophthalmology * Urology program launch * Build on non-proprietary formulations business * Continue evaluat
Slide 6: Slide 6
Slide 7: Slide 7